Kornimate/medical-research-clean huggingface dataset:
laryngomalacia study

Conditions: Laryngomalacia

Summary: noisy breathing is commonly caused by a floppy voicebox which is a condition called laryngomalacia. the cause of laryngomalacia is not fully understood, but some studies have suggested that it could be due to acid escaping from the stomach and spreading up the swallowing passage to the throat (acid reflux). this affects about 1 in 100 newborns and is therefore one of the most common reasons for infants to see otolaryngologists at bc children's hospital (bcch). these infants can have a spectrum of distressing symptoms including squeaky breathing, choking, difficulty feeding, failure to gain weight, and episodes of turning blue (due to lack of oxygen). at present, otolaryngologists at bcch will sometimes give children with laryngomalacia medication to reduce the amount of acid they make in their stomachs, in the hope that this will reduce their symptoms of laryngomalacia. it has never been scientifically confirmed whether anti-reflux medication will benefit these children any more than doing nothing at all.


Eligibility criteria:
inclusion criteria: * children less than 1 years old * children determined that they have laryngomalacia at the pediatric otolaryngology clinic at bc children's hospital. exclusion criteria:children cannot participate in this study if they have: * those already on anti-reflux medicine and considered medically unsafe to go through the washout period; * allergy to the trial medications; * nasogastric or permanent feeding tube; * other laryngeal abnormalities.

Keywords: laryngomalacia acid-reflux
evaluation study of the intestinal microbiota and quality of life in patients suffering from ibs treated with bifidice

Conditions: Irritable Bowel Syndrome

Summary: irritable bowel syndrome is the most common functional gastrointestinal disease and is characterized by high prevalence and chronic course.the pathology has a strong impact on the quality of life of affected patients and on health and social costs, these related to reduced productivity.the scarce efficacy and heavy side effects of traditional therapies lead these patients to often resort to alternative or complementary therapies. from the evaluation of the evidence of various probiotic preparations and food supplements, the investigators have used a commercial preparation characterized by the presence of bifidobacteria which have demonstrated some efficacy in thinking of improving the quality of life of these patients to evaluate quality of life, ability productivity and trend of some indices of disease severity in a small number of patients. these preliminary data could represent a starting point for more in-depth evaluations, also with placebo-controlled studies.


Eligibility criteria:
inclusion criteria: * patients aged ≥18 years * diagnosis of ibs according to rome iv criteria * mild to moderate disease, as measured by fbdsi * absence of signs and symptoms that may suggest organic damage and, if indicated, negative instrumental investigations (colonoscopy and/or imaging) * prescription of bifidice, according to normal clinical practice * informed consent expressed in written form exclusion criteria: * patients undergoing surgical resection of the stomach, gallbladder, small or large intestine * history of inflammatory bowel disease * severe sii, measured by fbdsi * active peptic ulcer * history of ischemic colitis * active infectious enteritis * diagnosed with hypo- or hyperthyroidism * need for pharmacological treatments for ibs, antibiotics, antidepressants and laxatives * therapy in progress with drug or supplements included in the list of those not allowed (paragraph n: to be established) * any disease that may affect gastrointestinal function and could interfere with appropriate assessment of abdominal pain or discomfort
observational study on monitoring nsaid-induced gastropathy in patients using magnetically-controlled capsule gastroscopy

Conditions: NSAID-Associated Gastropathy

Summary: the objective of this study is to observe gastric mucosal injuries in nsaid and non-nsaid users with magnetically-controlled capsule gastroscopy, and explore the effects of nsaids on gastric mucosal damage.

non-steroidal anti-inflammatory drugs are widely used in all kinds of people in china. a major limitation to their use is the adverse effects they cause on the gastrointestinal tract, including the formation of stomach lesions, ulcers due to stress reactions, and damage to the healing of gastric ulcers. the purpose of this prospective, single-center study was to monitor the gastric mucosal injury in patients with and without nsaids using magnetron capsule gastroscopy, and to explore the effect of nsaids on gastric mucosal injury. for people taking nsaids, it is necessary to regularly detect gastric mucosal damage, and timely intervention treatment is required if relevant lesions are found, and the medication plan is adjusted. magnetron capsule gastroscope has the advantages of comfort, safety, no anesthesia, no risk of cross infection, etc. it is highly accepted by the population, and is a beneficial supplement to traditional gastroscopy, so that some people with absolute or relative contraindications of traditional gastroscopy can get timely endoscopy, and can be diagnosed and treated early.

Eligibility criteria:
inclusion criteria: * planned magnetically-controlled capsule gastroscopy * nsaid use \>3 months or no nsaid use * informed consent exclusion criteria: * no surgical conditions or refuses abdominal surgery (once the capsule is stuck it cannot be removed surgically); * cardiac pacemakers (except mri-compatible ones); * electronic implants or metal foreign bodies; * pregnant women; * known or suspected gi obstruction, stenosis, fistula; * dysphagia.

Keywords: magnetically-controlled capsule endoscopy
clinical validation of new injection molded flocked nasopharyngeal swabs in response to the covid-19 pandemic

Conditions: COVID19

Summary: the sars-cov-2 pandemic has resulted in an international shortage of the nasopharyngeal (np) swabs used to collect sample for virological testing. this shortage has become a crisis as testing capacity is growing, and threatens to become the bottleneck at university of virginia health system and in the commonwealth of virginia, as it already is in other testing centers. to resolve this crisis, a team in the clinical microbiology laboratories at university of virginia medical center has been working closely with biomedical engineers in the university of virginia (uva), school of engineering and with high volume domestic manufacturers developing injection molded polypropylene flocked nylon np swab. this prototype will be tested for non-inferiority relative to existing, already validated np swabs ("control swab") for purposes of molecular microbiology: i.e. the polymerase chain reaction (pcr) tests used for virological testing for sars-cov-2. specifically, the nasopharynx of patients with covid-19 and patients under investigation (pui) for covid-19, the disease caused by sars-cov-2, will be swabbed using a prototype swab and a control swab (the standard of care swab), and test for concordance of sars-cov-2. in all cases the swab will be transported in validated fda cleared viral transport medium (vtm) as per standard operating procedure at university of virginia medical center.


Eligibility criteria:
inclusion criteria: * individuals presenting to the site for clinical care will be evaluated for clinical screening for covid-19 testing or other respiratory infection testing. * individuals felt identified clinically as needing covid-19 testing may be approached for study participation. * individuals already under clinical care that have tested positive for covid-19 will be approached for study participation. * volunteer health care workers who have approached the principal investigator exclusion criteria: * known thrombocytopenia of \<50,000 platelets/μl (risk of mild bleeding). * individuals presenting with an anatomically altered nasal cavity. * pregnant (self-reported) * no other patients will be specifically excluded.
an open-label, crossover study to assess the effect of food on the oral bioavailability and pharmacokinetic profile of 3'-deoxy-3'-fluorothymidine (flt) in asymptomatic human immunodeficiency virus (hiv)-infected subjects

Conditions: HIV Infections

Summary: to characterize the pharmacokinetics of orally administered flt (in a liquid formulation) after single doses in both the fed and fasting states; to assess the effect of food on the oral bioavailability of flt


Eligibility criteria:
inclusion criteria patients must have: * positive elisa test confirmed by western blot analysis. * asymptomatic. * willing to sign an informed consent. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * oral candida infection documented by morphology or by a response to antifungal therapy within two months prior to study entry. * oral hairy leukoplakia at any time prior to entry. * temperature \> 37.8 c. * any malignancy other than cutaneous basal cell carcinoma or cervical carcinoma in situ. * significant chronic underlying medical illness which would prevent continuous participation in this clinical trial. * unwilling to sign an informed consent. * zidovudine induced hematological toxicity. prior medication: excluded: * therapy with antiretroviral drugs or immunomodulators within seven days before entry. * therapy with any investigational drug during the preceding 30 days. patients may not have: * oral candida infection documented by morphology or by a response to antifungal therapy within two months prior to study entry. * oral hairy leukoplakia at any time prior to entry. * temperature \> 37.8 c. * any malignancy other than cutaneous basal cell carcinoma or cervical carcinoma in situ. * significant chronic underlying medical illness which would prevent continuous participation in this clinical trial. * unwilling to sign an informed consent. * zidovudine induced hematological toxicity.

Keywords: biological availability alovudine food
national child traumatic stress network (nctsn) quality improvement initiative database

Conditions: Post Traumatic Stress Disorder; Anxiety; Depression; Conduct Disorder; ADHD

Summary: trauma-informed treatment will improve emotional regulation and behavior.

the proposed study is to request permission to continue federally mandated data collection to examine the clinical outcomes of children at the family center at kennedy krieger institute who are enrolled in evidence-based and promising trauma-informed treatments as part of the national child traumatic stress network funded by the substance abuse and mental health services administration. the purpose of the national child traumatic stress initiative(nctsni) evaluation is to determine the extent to which the nctsi, through the national child traumatic stress network (nctsn), has raised the standard of care and improved access to services for traumatized children. in addition, the evaluation assesses the extent to which the nctsi has served as a national resource capable of improving children's access to high-quality, trauma-informed mental health services. this data, previously collected and managed by the category i nctsn center at duke will now be managed by icf macro in a data system entitled nicon.

Eligibility criteria:
inclusion criteria: * children enrolled in treatment at the family center and caregivers exclusion criteria: * psychosis, * inability to comply with directions

Keywords: child trauma maltreatment physical abuse sexual abuse emotional abuse abandonment domestic violence community violence
clinical decision support for patient migraine management

Conditions: Migraine

Summary: little is known about who adheres to migraine management strategies, and circumstances that enhance adherence. this knowledge is required to develop patient-level interventions to improve adherence to migraine management strategies. the proposed project will pilot the first patient level intervention designed to improve adherence to preventive and acute migraine management strategies. the study will identify people most at risk for non-adherence to migraine management strategies. participants will be randomly assigned to receive a tailored clinical decision support tool or education intervention.

participants with a diagnosis with migraine who currently meet criteria for episodic migraine (migraine with headaches that occur on fewer than 15 days per month) will be recruited from local providers. after an initial screening, eligible participants will complete 30 days of monitoring 3 times daily on an electronic headache diary (a smartphone app) to confirm study eligibility. participants whose eligibility is confirmed will complete an additional 2 months (60 days) of monitoring headache activity and adherence to acute and preventive (medication and behavioral) strategies recommended for people with migraine. participants who show suboptimal adherence during the first 3 months of monitoring (\<50% of eligible days) will be eligible to continue to the intervention component of the study. participants who choose to continue in the study will be randomized to receive a tailored clinical decision support tool or education intervention, both delivered through the smartphone app. participants will continue to self-monitor, with the intervention components active, for 3 months.

Eligibility criteria:
inclusion criteria: * have an international classification of headache disorders - 3 beta diagnosis of migraine * self-report and diary-confirmed 6 to 14 headache days per month * are currently prescribed a triptan for acute migraine management * are stable on current preventive and acute treatment regimen for migraine * are between the ages of 18 and 65 * reads and understands english * has capacity to consent * completes 80% of diary recordings in the first 30 days of monitoring exclusion criteria: * probable or confirmed medication overuse headache * a plan to change, or changing preventive or acute migraine medication during study participation * are pregnant or are planning to become pregnant during study involvement (as triptans are category c medications) * psychiatric illness or cognitive difficulties that would interfere with participation in the study * participated in the pilot development of the intervention evaluated by this research protocol.
the value of 68ga-fapi pet/ct in the efficacy evaluation of advanced unresectable hepatocellular carcinoma patients undergoing systemic antitumor therapy

Conditions: Hepatocellular Carcinoma (HCC)

Summary: this study aims to investigate the value of 68ga-fapi pet/ct in the efficacy evaluation of advanced unresectable hepatocellular carcinoma patients undergoing systemic antitumor therapy.

the investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. all participants will undergo a 68ga-fapi pet/ct before treatment and after 3-month treatment. the imaging response measurements will be compared with the histopathological results as gold standard.

Eligibility criteria:
inclusion criteria: 1. pathological and clinical diagnosis of advanced unresectable hepatocellular carcinoma patients. 2. signed and dated informed consent form. 3. commitment to comply with research procedures and co-operation in the implementation of the full research process. 4. aged 18-75 years old. exclusion criteria: 1. patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc. 2. intestinal perforation, complete intestinal obstruction 3. pregnant women and women who may be pregnant, women who are breastfeeding. 4. non-compliant person

Keywords: hepatocellular carcinoma 68ga-fapi pet/ct
a retrospective study to investigate the additive effectiveness of chinese herbal medicine in alzheimer's disease

Conditions: Alzheimer Disease

Summary: in china, herbal therapy as a complementary therapy is very popular. should conventional therapy (such as donepezil and memantine) combined with herbal therapy make add-on benefit? cognition, activities of daily living and behavioral symptoms will be assessed. data will be collected from the medical records of patients with alzheimer's disease (ad) in memory clinics.

conventional therapy (ct), such as donepezil and memantine are well- known short-term treatments for the symptoms of alzheimer's disease (ad). the efficacy of them, however, drops below baseline level after 9 months. should chinese herbal medicine make add-on benefit? the grape formula was designed by prof. j tian, a prepared granules of chinese herbs, according to qifuyin in jing yue quan shu (published in a.d. 1624). patients treated with ct+herbal therapy or ct alone for up to and over 12 months are collected. cognition, activities of daily living and behavioral symptoms are selected as outcomes for assessing the effectiveness.

Eligibility criteria:
inclusion criteria: * gradual and progressive change in cognitive functions for a period greater than 6 months; * objective evidence of significantly impaired episodic memory together with at least one of other cognitive domains on testing; * global cognitive decline measured by mini-mental state examination (mmse) adjusted for education: ≤22 for illiteracy, ≤23 for primary school, ≤24 for middle school,≤26 for high education; * impaired abilities of daily living, adls score ≥16; * clinical dementia rating (cdr) total score 0.5\~3.0; * ≤4 point on hachinski ischaemic score (his); * age-adjusted medial temporal lobe atrophy scale (mta-scale) based on coronary magnetic resonance imaging (mri) scan of the brain (1.0 or more for ≤65 years; 1.5 or more for ≤75 years and 2.0 or more for ≥75 years); * other causes of dementia excluded. exclusion criteria: * sudden onset of cognitive disorder with focal nervous system signs in the early stages of disease, (e.g., incomplete paralysis, anesthesia, dysfunctional visual field, and dystaxia); * early occurrence of the following symptoms: gait disturbances, seizures, extrapyramidal signs, hallucinations and cognitive fluctuations; * any major psychiatric disorders (e.g., dsm-iv(diagnostic and statistical manual of mental disorders) defined psychosis, major depression, bipolar disorder, or alcohol or substance abuse); * other conditions that may explain cognitive impairment (e.g., hypothyroidism, electrolyte imbalance, toxic, inflammatory, and metabolic disorders).

Keywords: complementary therapies
study of pembrolizumab (mk-3475) in participants with relapsed or refractory classical hodgkin lymphoma (mk-3475-087/keynote-087)

Conditions: Hodgkin Lymphoma

Summary: this is a study of pembrolizumab (mk-3475) for participants with relapsed/refractory classical hodgkin lymphoma (rrchl) who: 1) have failed to achieve a response or progressed after autologous stem cell transplant (auto-sct) and have relapsed after treatment with or failed to respond to brentuximab vedotin (bv) post auto-sct or 2) were unable to achieve a complete response (cr) or partial response (pr) to salvage chemotherapy and did not receive auto-sct, but have relapsed after treatment with or failed to respond to bv or 3) have failed to achieve a response to or progressed after auto-sct and have not received bv post auto-sct. the primary study hypothesis is that treatment with single agent pembrolizumab will result in a clinically meaningful overall response rate.


Eligibility criteria:
inclusion criteria: * relapsed or refractory de novo classical hodgkin lymphoma * participant may have failed to achieve a response to, progressed after, or be ineligible for autologous stem cell transplant (auto-sct) * participant may have failed to achieve a response or progressed after treatment with brentuximab vedotin or may be brentuximab vedotin naïve * eastern cooperative oncology group (ecog) performance status of 0 or 1 * measurable disease * adequate organ function exclusion criteria: * diagnosis of immunosuppression or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication * prior monoclonal antibody within 4 weeks prior to study day 1 or chemotherapy, targeted small molecular therapy, or radiation therapy within 2 weeks prior to study day 1 * prior allogeneic hematopoietic stem cell transplantation * known clinically active central nervous system involvement * known additional malignancy that is progressing or requires active treatment * has a known history of human immunodeficiency virus (hiv) * has known active hepatitis b (hbv) or hepatitis c (hcv) * active autoimmune disease requiring systemic treatment in past 2 years * has a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis

Keywords: pd1 pd-1 pdl1 pd-l1
the role of m6a rna modification in moyamoya disease

Conditions: Moyamoya Disease

Summary: the purpose of this study is to detect the change of m6a rna modification from peripheral blood of patients with moyamoya disease, and to assess the relationship between clinical characteristics.

moyamoya disease (mmd) is a rare cerebrovascular disorder characterized by occlusion of bilateral internal carotid and intracerebral arteries with the compensatory growth of fragile small vessels. the etiology of disease is still unclear. the pathology is associated with blood vessels, characterizing the molecular changes of blood in patients with mmd may yield insights into the disease. n6-methyladenosine (m6a) is identified to be the most common and abundant rna molecular modification in eukaryotes, and involves in a variety of metabolic processes of rna, such as rna transcription, shearing, nuclear transport, and translation ability. the propose of this study is to investigate the change of m6a rna modification in patients blood with moyamoya disease and its influence on clinical indicators, aiming to provide potential pathogenesis of moyamoya disease.

Eligibility criteria:
health volunteers' inclusion criteria: age between 4-60; male or female; exclusion criteria: exclude the volunteers with history of cerebrovascular disease.

Keywords: m6a
silver nitrate vs. triamcinolone for treatment of hypergranulation tissue

Conditions: Wound Healing; Granulation Tissue

Summary: this randomized controlled trial aims to compare the efficacy of silver nitrate, triamcinolone, and a successive use of both treatments in managing hypergranulation tissue in traumatic wounds. conducted over a four-year period at upmc mercy, the study will involve patients presenting with hypergranulation tissue. participants will be randomly assigned to receive either topical silver nitrate, topical triamcinolone, or a combination of the two in succession. the study will assess treatment outcomes based on the reduction or resolution of hypergranulation tissue, with the goal of identifying the most effective therapeutic approach. this research will provide valuable insights into optimizing treatment strategies for hypergranulation tissue in traumatic wounds.


Eligibility criteria:
inclusion criteria: * patients must be 18 years or older. * patients must be admitted to the institution with non-infected, traumatic wounds exhibiting hypergranulation tissue. * patients must provide consent to participate in the study. * eligible wounds include superficial or partial-thickness wounds. * wounds will be categorized based on size and depth, with variations controlled for in the statistical analysis. exclusion criteria: * patients with known allergies or contraindications to silver nitrate or triamcinolone. * patients with wounds that do not exhibit hypergranulation tissue. * patients with wounds not primarily due to traumatic injury (e.g., surgical wounds, pressure ulcers). * full-thickness, infected, or complex wounds will be excluded, as these may require different management strategies.